Bibliography
- KASTRATI A, MEHILLI J, SCHUHLEN H et al: A clinical trial of abciximab in elective percutaneous oronary intervention after pretreatment with clopidogrel. N Engl. J. Med. (2004) 350(3):232–238.
- ••The TSAR-REACT trial evaluated whethertreatment with the GP II13/IIIa inhibitor abciximab reduces post-procedure ischaemic complications in low-risk patients pretreated with clopidogrel who undergo coronary stenting.
- MEHILLI J, KASTRATI A, SCHUHLEN H et al: Randomised clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation (2004) 110(24):3627–3635.
- ••The TSAR-SWEET trial evaluatedtreatment with abciximab compared with placebo in diabetic patients undergoing elective PCI and pretreated with a high loading dose of clopidogrel.
- AL SUWAIDI J, HOLMES DR Jr, SALAM AM, LENNON R, BERGER PB: Impact of coronary artery stents on mortality and nonfatal myocardial infarction: meta-analysis of randomized trials comparing a strategy of routine stenting with that of balloon angioplasty. Am. Heart J. (2004) 147(5):815–822.
- •This meta-analysis showed that in comparison with percutaneous transluminal coronary angioplasty (PTCA), stenting results in a significant reduction in the frequency of major adverse cardiac events after PCI driven mainly by a reduction in target vessel revascularisation. STEINHUBL SR, BERGER PB, MANN JT et al.: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomised controlled trial. JAMA (2002) 288:2411-2420. In this trial patients who received clopidogrel 6 h before PCI experienced a relative risk reduction of 38.6% compared with no reduction with treatment 6 h before PCI.
- SALAM AM, SUWAIDI JA: Platelet glycoprotein IIb/IIIa antagonists in clinical trials for the treatment of coronary artery disease. Expert Opin. Investig. Drugs (2002) 11(10:1645–1658.
- •An excellent review of clinical trials of platelet glycoproteininhibitors.
- SCHOMIG A, NEUMANN FJ, KASTRATI A et al: A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary artery stents. N Engl. I Med. (1996) 334:1084–1089.
- LEON MB, BAIM DS, POPMA JJ et al: A clinical trial comparing three antithrombotic-drug regimens after coronary artery-stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl. J. Med. (1998) 339:1665–1671.
- THEBAULT JJ, KIEFFER G, CARIOU R: Single-dose pharmacodynamics of clopidogrel. Semin. Thromb. Hemost. (1999) 25\(Suppl. 2):3–8.
- MOLLER I, SEYFARTH M, RODIGER S et al.: Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart (2001) 85:92–93.
- PACHE J, KASTRATI A, MEHILLI J et al.: Clopidogrel therapy in patients undergoing coronary stenting: value of a high-loading-dose regimen. Catheter Cardiovasc. Interv. (2002) 55:436–441.
- ROFFI M, TOPOL EJ: Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes. Eur. Heart J. (2004) 25:190–198.